MedTrace Logo

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

NCT04585490 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-05-04

No results posted yet for this study

Summary

The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy

Conditions

  • Non Small Cell Lung Cancer
  • NSCLC, Stage III
  • Nsclc

Interventions

DRUG

Durvalumab

Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)

DRUG

Carboplatin

Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle

DRUG

Pemetrexed

500mg/m2 on Day 1 of every 21-day cycle

DRUG

Paclitaxel

175mg/m2 on Day 1 of every 21-day cycle

DRUG

Cisplatin

Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin

DEVICE

AVENIO ctDNA Surveillance Kit

Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

DRUG

Tremelimumab

not to exceed 75mg IV on Day 1 of every 21-day cycle

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Maximilian Diehn

    lead OTHER

Principal Investigators

  • Maximilian Diehn, MD · Stanford Universiy

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-25
Primary Completion
2026-08-31
Completion
2028-04-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04585490 on ClinicalTrials.gov